We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Blind Spots in Development of Nanomedicines.
- Authors
Salvi, Bhagyashree V.; Kantak, Maithali; Kharangate, Kalyani; Trotta, Francesco; Maher, Timothy; Shende, Pravin
- Abstract
The field of nanomedicine demonstrates immense advantages and noteworthy expansion compared to conventional drug delivery systems like tablet, capsules, etc. Despite the innumerable advantages, it holds certain shortcomings in the form of blind spots that need to be assessed before the successful clinical translation. This perspective highlights the foremost blind spots in nanomedicine and emphasizes the challenges faced before the entry into the market, including the need for provision of safety and efficacy data by the regulatory agencies like FDA. The significant revolution of nanomedicine in the human life, particularly in patient well-being, necessitates to identify the blind spots and overcome them for effective management and treatment of ailments.
- Subjects
UNITED States. Food &; Drug Administration; NANOMEDICINE; DRUG delivery systems; GOVERNMENT agencies; MARKET entry
- Publication
Technology in Cancer Research & Treatment, 2024, p1
- ISSN
1533-0346
- Publication type
Article
- DOI
10.1177/15330338241245342